We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Genetic Background and Clinicopathologic Features Established for Adult-Onset Nephronophthisis

By LabMedica International staff writers
Posted on 06 May 2021
Print article
Image: The Hamamatsu Photonics Nanozoomer 1 Digital Slide Scanner (Photo courtesy of University of Adelaide)
Image: The Hamamatsu Photonics Nanozoomer 1 Digital Slide Scanner (Photo courtesy of University of Adelaide)
Nephronophthisis (NPH) is a genetic disorder of the kidneys which mainly affects children. It is classified as a medullary cystic kidney disease. The disorder is inherited in an autosomal recessive fashion and, although rare, is the most common genetic cause of childhood kidney failure.

Even in adult patients, accurate diagnosis of NPH is important because management options, such as kidney transplantation and appropriate genetic counseling, are available. The clinical diagnosis of adult NPH is problematic because clinical, radiologic and histologic features are non-specific. Even the extrarenal features are fewer in adults. Because management includes renal transplantation and genetic counseling, an accurate early diagnosis is essential.

Nephrologists at the Tokyo Medical and Dental University (Tokyo, Japan) investigated 18 adult patients who were suspected to have NPH by renal biopsy. The patients were recruited at 16 institutions in Japan between 2015 and 2019. For each patient, the tissue slides that were stained with hematoxylin-eosin, periodic acid-Schiff, and periodic acid–methenamine silver were digitized using the NanoZoomer HT Scan system (Hamamatsu Photonics, Hamamatsu, Japan).

Comprehensive genetic testing was performed using capture-based next-generation sequencing of 69 genes that cause nine types of hereditary cystic kidney disease, including NPH, NPH-related ciliopathies (Joubert syndrome, Meckel syndrome, Senior-Løken syndrome, Bardet-Biedl syndrome, and skeletal ciliopathies), autosomal dominant polycystic kidney disease, autosomal recessive polycystic kidney disease, and autosomal dominant tubulointerstitial kidney disease.

The scientists performed polymerase chain reaction for exons 1, 10, and 20 of NPHP1, if homozygous entire deletion of NPHP1 was detected by copy number variation analysis. To investigate what the essence of thick tubular basement membrane (TBM) duplication was, they performed low-vacuum scanning electron microscopic (Hitachi, Tokyo, Japan) analysis and immunofluorescence (IF) analysis in the representative cases with or without pathogenic mutations.

The investigators reported that seven of 18 patients had pathogenic NPH-causing mutations in NPHP1, NPHP3, NPHP4, or CEP164. Compared with patients without pathogenic mutations, those with pathogenic mutations were significantly younger, but did not significantly differ in the classic NPH pathologic findings, such as tubular cysts. On the other hand, the number of tubules with thick TBM duplication, which was defined as >10-μm thickness, was significantly higher in patients with genetically proven adult NPH than in those without pathogenic mutations. α-Smooth muscle actin (α-SMA)-positive myofibroblasts were detected inside thick TBM duplication.

The authors concluded that in adult patients with NPH, thick TBM duplication was the specific finding. Their analysis also suggested that older patients tended to have no pathogenic mutations, even when they were suspected to have NPH by renal biopsy. These findings could be the novel clinical clue for the diagnosis of NPH in adult patients. The study was published originally on March 3, 2021 in the journal Kidney International Reports.

Related Links:
Tokyo Medical and Dental University
Hamamatsu Photonics
Hitachi


Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
HbA1c Test
HbA1c Rapid Test
New
Cytomegalovirus Test
NovaLisa Cytomegalovirus (CMV) IgG Test

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: The advanced molecular test is designed to improve diagnosis of a genetic form of COPD (Photo courtesy of National Jewish Health)

Groundbreaking Molecular Diagnostic Test Accurately Diagnoses Major Genetic Cause of COPD

Chronic obstructive pulmonary disease (COPD) and Alpha-1 Antitrypsin Deficiency (AATD) are both conditions that can cause breathing difficulties, but they differ in their origins and inheritance.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more